KALA BIO, Inc. (KALA) |
| 0.2555 -0.005 (-1.73%) 10-14 12:09 |
| Open: | 0.252 |
| High: | 0.2646 |
| Low: | 0.2512 |
| Volume: | 0 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.09 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.61 |
| Resistance 1: | 0.47 |
| Pivot price: | 0.38 |
| Support 1: | 0.25 |
| Support 2: | 0.21 |
| 52w High: | 95.5 |
| 52w Low: | 0.2512 |
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Financials
| EPS | -10.710 |
| Book Value | 0.470 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -65.4 |
| Return on Equity (ttm) | -345.3 |
Company news
Thu, 01 Oct 2026
Kala Bio Inc (KALA-Q) Stock Price and News - The Globe and Mail
Wed, 30 Sep 2026
KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why - Benzinga
Tue, 29 Sep 2026
Kala Bio signs letter of intent to acquire telehealth firm - Investing.com
Tue, 29 Sep 2026
A telehealth platform has generated over $48 million in sales since 2023. KALA Bio may buy it. - Stock Titan
Thu, 24 Sep 2026
A U.S. DNA platform may resell Virotek's genetic tests beyond eye care. - Stock Titan
Thu, 24 Sep 2026
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
